TMS for Smoking Cessation in PLWHA Cessation in People Living With HIV/AIDS (PLWHA)

Sponsor
Gopalkumar Rakesh (Other)
Overall Status
Recruiting
CT.gov ID
NCT04936594
Collaborator
(none)
40
1
2
11.2
3.6

Study Details

Study Description

Brief Summary

The pilot study proposal aims to modulate craving and attentional bias towards smoking cues in 40 people living with HIV/AIDS (PLWHA) using transcranial magnetic stimulation (TMS), with functional MRI (fMRI) brain correlates. TMS is a form of noninvasive brain stimulation and modulates neural activity using tiny doses of focused electricity. For the study, participants would perform two cognitive tasks and neuroimaging before and after the TMS and investigators would compare changes in these paradigms with TMS. The investigators will also get a point of contact urine drug screen before study initiation. The investigators will aim to recruit 20 subjects in each arm of our trial (total of 40) from the BlueGrass HIV Clinic.

Condition or Disease Intervention/Treatment Phase
  • Device: iTBS
  • Device: Sham TMS
N/A

Detailed Description

People living with HIV/AIDS (PLWHA) smoke at nearly three times the rate of the general population. These extraordinary smoking rates are associated with greater AIDS-related cancer, non-AIDS related morbidity including non-AIDS-defining cancer, cardiovascular disease, pulmonary disease, and mortality. Smoking significantly impacts the progression and outcome of HIV disease and has been identified as the leading contributor to premature mortality in PLWHA. Suboptimal results with current smoking cessation strategies makes identifying new adjunct strategies an area of need. The pilot study proposal aims to modulate craving and attentional bias towards smoking cues in people living with HIV/AIDS (PLWHA) using transcranial magnetic stimulation (TMS), with functional MRI (fMRI) brain correlates. TMS is a form of noninvasive brain stimulation and modulates neural activity using tiny doses of focused electricity. The TMS paradigm we would be performing is called theta burst stimulation (TBS), which is potent, short, and efficient. It has shown to cause neuroplasticity even with a single session and was approved by the FDA for treatment of major depressive disorder in 2019.

Targeting the left dorsolateral prefrontal cortex (DLPFC) by using MNI coordinates (-44,40,29) via Brainsight Neuronavigation will modulate craving and attentional bias that is closely associated with craving. For this pilot study, 40 participants will perform the attentional bias task, craving scale and neuroimaging before and after the TBS/ sham TMS session, to compare changes in these paradigms between these interventions. Attentional bias would be measured with eye tracking, craving will be assessed with tobacco craving questionnaire (TCQ-SF). The investigators will aim to recruit 20 subjects in each arm of the trial (total of 40) from the BlueGrass HIV Clinic, who have an established pipeline for enrolling PLWHA patients in clinical trials. Although there is limited data on TMS in smoking, there have been no TMS studies done in PLWHA

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Done by MagVenture TMS device
Primary Purpose:
Treatment
Official Title:
Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in People Living With HIV/AIDS (PLWHA)
Actual Study Start Date :
May 24, 2021
Anticipated Primary Completion Date :
Apr 30, 2022
Anticipated Study Completion Date :
Apr 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intermittent Theta Burst Stimulation (iTBS)

Subjects randomized to the experimental arm will receive 1800 pulses of intermittent TBS using MagVenture B65 A/P coil

Device: iTBS
1800 pulses of iTBS

Sham Comparator: Sham TMS

Sham TMS will be delivered using MagVenture B65 A/P coil

Device: Sham TMS
Sham TMS

Outcome Measures

Primary Outcome Measures

  1. Attentional Bias [Baseline]

    Measured using visual probe task administered (adapted for smoking images) on a computer and eye tracker

  2. Attentional Bias [Four hours after baseline assessment]

    Measured using visual probe task (adapted for smoking images) administered on a computer and eye tracker

Secondary Outcome Measures

  1. Tobacco craving questionnaire (TCQ) [Baseline]

    Craving measured using TCQ

  2. Tobacco craving questionnaire (TCQ) [Four hours from baseline]

    Craving measured using TCQ

Other Outcome Measures

  1. Resting State Functional Connectiivity [Baseline]

    Measured in MRI scanner

  2. Resting State Functional Connectiivity [Four hours from baseline]

    Measured in MRI scanner

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients enrolled in the Bluegrass Clinic

  • Confirmed chart diagnosis of a HIV and receiving HIV treatment at the participating HIV clinic

  • Age 18-60 years

  • Preferably right hand dominant

  • Currently self-report smoking 10 of more cigarettes per day or a score of > 5 on the Fagerstrom Test for Nicotine

  • Willing and able to abstain from all drug use

  • Exhaled breath on day of study CO < 10 ppm

  • Stabilized on maintenance buprenorphine if having comorbid opioid use disorder

  • Able to read and speak English

  • Able to provide informed consent to participate.

Exclusion Criteria:
  • Pregnant, nursing, or becoming pregnant during the study

  • History of traumatic brain injury or seizures which are contraindications for transcranial magnetic stimulation (TMS)

  • Increased risk of seizure for any reason, including prior diagnosis of epilepsy, seizure disorder, increased intracranial pressure, or history of significant head trauma with loss of consciousness for ≥ 5 minutes which are all contraindications for TMS

  • Presence of intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants, or electrodes), cardiac pacemakers, or vagus nerve stimulation device which are all contraindications for magnetic resonance imaging

  • Neurological disorder including, but not limited to: space occupying brain lesion; any history of seizures, history of cerebrovascular accident; fainting, cerebral aneurysm, major neurocognitive disorder, Huntington chorea; multiple sclerosis which are all contraindications for TMS.

Contacts and Locations

Locations

Site City State Country Postal Code
1 245 Fountain Court Lexington Kentucky United States 40509

Sponsors and Collaborators

  • Gopalkumar Rakesh

Investigators

  • Principal Investigator: Gopalkumar Rakesh, MD, Assistant Professor, University of Kentucky

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gopalkumar Rakesh, Assistant Professor, University of Kentucky
ClinicalTrials.gov Identifier:
NCT04936594
Other Study ID Numbers:
  • 64473
First Posted:
Jun 23, 2021
Last Update Posted:
Jun 30, 2021
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Gopalkumar Rakesh, Assistant Professor, University of Kentucky
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 30, 2021